Cover Image
市場調查報告書

全球胜肽癌症疫苗市場及臨床實驗平台趨勢

Global Peptide Cancer Vaccine Market & Clinical Pipeline Insight

出版商 KuicK Research 商品編碼 352104
出版日期 內容資訊 英文 142 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球胜肽癌症疫苗市場及臨床實驗平台趨勢 Global Peptide Cancer Vaccine Market & Clinical Pipeline Insight
出版日期: 2016年02月01日 內容資訊: 英文 142 Pages
簡介

在基於單株抗體的免疫療法,抗體·藥物複合體,樹狀細胞癌症疫苗等五花八門的癌症免疫療法中,胜肽癌症疫苗由於作用機制與製造流程,以及對使用者而言出色的適用性而建立了特殊地位。

本報告提供全球胜肽癌症疫苗市場及臨床實驗平台趨勢相關調查,彙整胜肽癌症疫苗的概要與作用機制,需求,開發平台趨勢,及參與企業的競爭趨勢等資料。

第1章 胜肽癌症疫苗:簡介

第2章 胜肽癌症疫苗的作用機制

  • 藉由胜肽癌症疫苗而活化的免疫學細胞
  • 合成胜肽疫苗開發次序

第3章 針對急性骨髓性白血病,來自WT1癌蛋白的合成胜肽類比臨床實驗有效性研究

  • 這個研究的基本概要
  • WT1胜肽的簡介
  • 臨床實驗干預的手法
  • 臨床實驗結果

第4章 胜肽癌症疫苗對主要癌症的廣泛作用

  • 胜肽和大腸癌
  • 胜肽和肺癌
  • 胜肽和胰臟癌
  • 胜肽和胃癌
  • 胜肽和前列腺癌
  • 胜肽和乳癌

第5章 胜肽癌症疫苗市場近幾年趨勢

  • 優化的潛在胜肽
  • 治療方法CpG胜肽基癌症疫苗
  • 合成長胜肽的個體化新抗原疫苗接種
  • 重組胜肽疫苗
  • p53胜肽脈衝樹狀細胞癌症疫苗

第6章 全球胜肽癌症疫苗開發平台概要

第7章 推動市場的要素:為何是胜肽癌症疫苗

  • 活化的免疫療法
  • 個體化·標靶治療
  • 高效率,高免疫抗原性反應
  • 以複數腫瘤為目標的能力
  • 對免疫抗性的有效解決辦法
  • 生活品質和成本效益的改善

第8章 胜肽癌症疫苗的課題:為何未來將愈加嚴苛

  • 臨床實驗參數
  • 單一抗原胜肽疫苗:高失敗可能性
  • 缺乏為了評價臨床實驗結果的標準化參數
  • 為了各種患者的有效治療方法
  • 癌症免疫編輯

第9章 企業,適應,各期開發平台

第10章 結論:胜肽癌症疫苗癌症免疫療法的有效候補

第11章 競爭環境

圖表

目錄

With the ever increasing new cancer cases across the globe and the conventional treatment methods unable to cope up with the challenges posed by the tumor and their immune response evading techniques, cancer immunotherapy brings a ray of hope. Cancer immunotherapy allows the host's immune cells to get sensitized with the tumor-associated antigens which in turn elicits B cell and T cell mediated immune response to target and eliminate tumor cells. This is the underlying principle of cancer immunotherapy.

Among different forms of cancer immunotherapy which includes monoclonal antibody based immunotherapy, antibody-drug conjugates, dendritic cell cancer vaccines and others, peptide cancer vaccine holds a special position due to its various inherent advantages associated with its mechanism of action, its manufacturing process and its user friendly compliance. This could be supported with the fact that the first cancer vaccine successfully launched in the market was provenge, a prostate cancer vaccine.

The market trends of peptide cancer vaccines are on a higher curve, thanks to so many favorable parameters associated with peptides. Peptide cancer vaccines are based on active immunotherapy which makes them more potent as the antibodies present in the body after the administration of the vaccine are already sensitized and are ready for their anti-tumor action. The response is permanent which lasts almost throughout the lifetime of the patient.Moreover, peptides are highly specific in their function which allows for the formulation of personalized cancer vaccine. As the tumor-associated antigens are protein sequence, they can be investigated and incorporated for the development of cancer vaccine based on that specific protein sequence to target only the tumor cells, avoiding the healthy cells hence reduced risk of toxicity.

With the development of next generation peptide cancer vaccines namely multivalent long peptides, peptide cocktail vaccines, hybrid peptide vaccines, personalized peptide vaccines and peptide-pulsed dendritic cell cancer vaccines among others, several challenges associated with the cancer immunotherapy will be addressed. The major hurdles for peptide cancer vaccines is the lack of standardized clinical trials success related parameters which has resulted in many clinical trials failures in the recent times. In addition to this, cancer cells are known to evade immune response by modulating the immune system, inducing immune-tolerance and initiating cancer-immunoediting.

What so ever be the challenges, the future of peptide cancer vaccine is extremely bright as it offers novel solutions to so many unanswered questions in cancer immunotherapy. As the knowledge of antigen, its action on the key components of the immune system is further understood, the efficacy of peptide vaccine will definitely increase. Until then, the best way forward for peptide cancer vaccine is to use multivalent long peptide sequence which is able to break immunotolerance and offer wide therapeutic action. Meanwhile investigators need to bring forward new clinical trials study parameters in line with the cancer vaccine program. For the patients at their advanced stage of cancer, the combinational therapy using conventional methods like chemotherapy, surgery needs to be undertaken along with immunotherapy for effective anti-cancer therapeutics.

“Global Peptide Cancer Vaccine Market & Clinical Pipeline Insight” Report Highlights:

  • Introduction to Peptide cancer Vaccine
  • Mechanism of Action of Peptide Cancer Vaccine
  • Need of Peptide Cancer Vaccines
  • Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained From WT1 Oncoprotein
  • Wide Spectrum Action of Peptide Cancer Vaccines against Major Cancer
  • Global Peptide Cancer Vaccine Pipeline: 41 Vaccines
  • Global Peptide Cancer Vaccine Clinical Pipeline by Company, Indication & Phase

Table of Contents

1. Peptide Cancer Vaccine: Introduction

2. Mechanism of Action of Peptide Cancer Vaccines

  • 2.1. Immunological Cells Activated by Peptide Cancer Vaccines
  • 2.2. Procedure of Synthetic Peptide Vaccine Development
    • 2.2.1. Determination of Antigen Components, Its Selection & Construction
    • 2.2.2. Peptide Immunogen Construction
    • 2.2.3. Immunogen Engineering Mechanism
    • 2.2.4. Adjuvants Used for Peptide Cancer Vaccines
    • 2.2.5. Investigation of Efficiency & Immune Response to Synthetic Peptide Cancer Vaccine

3. Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained from WT1 Oncoprotein against Acute Myeloid Leukemia

  • 3.1. Basic Layout of the Study
  • 3.2. Introduction to WT1 Peptide
  • 3.3. Methodologies Involved In the Clinical Study
    • 3.3.1. Trial Design Undertaken
    • 3.3.2. Treatment Procedure
    • 3.3.3. The Formulation of Vaccine Doses
    • 3.3.4. Assessment of CD4+ T cell & CD8+ T Cell Responses
  • 3.4. Results of the Clinical Trial Study
    • 3.4.1. Patients Immunological Parameters & the Clinical Outcomes
    • 3.4.2. Safety & Toxicity Related Clinical Outcomes

4. Wide Spectrum Action of Peptide Cancer Vaccines against Major Cancer

  • 4.1. Peptides & Colorectal Cancer
  • 4.2. Peptides & Lung Cancer
  • 4.3. Peptides & Pancreatic Cancer
  • 4.4. Peptides & Gastric Cancer
  • 4.5. Peptides & Prostate Cancer
  • 4.6. Peptides & Breast Cancer

5. Recent Trends in Peptide Cancer Vaccine Market

  • 5.1. Optimized Cryptic Peptides
  • 5.2. Therapeutic CpG Peptide-Based Cancer Vaccine
  • 5.3. Personalized Neoantigen Vaccination with Synthetic Long Peptides
  • 5.4. Recombinant Peptide Vaccine
  • 5.5. p53. Peptide-Pulsed Dendritic Cells Cancer Vaccines

6. Global Peptide Cancer Vaccine Pipeline Overview

7. The Market Driving Factors: Why Peptide Cancer Vaccines?

  • 7.1. An Active Immunotherapy
  • 7.2. Personalized & Targeted Therapy
  • 7.3. Highly Efficient, High Immunogenic Response Generating
  • 7.4. Multiple Tumor Targeting Ability
  • 7.5. A Viable Solution to Immunotolerance
  • 7.6. Improves the Quality Of Life & is Cost Effective

8. The Challenges Ahead For Peptide Cancer Vaccine: Why the Going Could Be Tough?

  • 8.1. The Parameters Related To the Clinical Trials
  • 8.2. Single Antigen Based Peptide Vaccine: Highly Prone To Failure
  • 8.3. Lack of Standardized Parameters for Assessing the Result of Clinical Trials
  • 8.4. Variable Therapeutic Window for Different Patients
  • 8.5. Cancer Immunoediting: The Three Es; Tumor Elimination, Equilibrium & Escape

9. Global Peptide Cancer Vaccine Clinical Pipeline by Company, Indication & Phase

  • 9.1. Research
  • 9.2. Preclinical
  • 9.3. Phase-I
  • 9.4. Phase-I/II
  • 9.5. Phase-II
  • 9.6. Phase-III

10. Conclusion: Peptide Cancer Vaccine; a Promising Candidate of Cancer Immunotherapy

11. Competitive Landscape

  • 11.1. Enzo Life Science (Alexis Biotech)
  • 11.2. Antigen Express
  • 11.3. BioLife Science
  • 11.4. Immatics Biotechnologies
  • 11.5. Immune Design
  • 11.6. Imugene
  • 11.7. Immunomedics
  • 11.8. ISA Pharmaceuticals
  • 11.9. Galena Biopharma
  • 11.10. Generex Biotechnology Corporation
  • 11.11. Lytix Biopharma
  • 11.12. Merck (Merck Serono)
  • 11.13. OncoTherapy Science
  • 11.14. Oncothyreon
  • 11.15. Pfizer
  • 11.16. Phylogica
  • 11.17. Symphogen (Receptor BioLogix)
  • 11.18. Sumitomo Dainippon Pharma
  • 11.19. TapImmune
  • 11.20. Vaxon Biotech

List of Figures

  • Figure 1-1: Advantages of Peptide Cancer Vaccines
  • Figure 2-1: Immunological Cells Activated By Peptide Cancer Vaccines
  • Figure 2-2: Procedure of Synthetic Peptide Cancer Vaccine Development
  • Figure 2-3: Determination of Antigen Components, Its Selection & Construction
  • Figure 2-4: Role of Adjuvants in Peptide Cancer Vaccines
  • Figure 2-5: Investigation of Efficiency & Immune Response to Synthetic Peptide Cancer Vaccine
  • Figure 3-1: Clinical Trial Study of WT1 Peptide Vaccine for Acute Myeloid Leukemia Patients
  • Figure 3-2: WT1 Peptide as a Marker for Cancer Therapy
  • Figure 3-3: Methodologies Involved In the Clinical Study
  • Figure 4-1: Peptides & Colorectal Cancer
  • Figure 4-2: Peptides & Lung Cancer
  • Figure 4-3: Peptides & Pancreatic Cancer
  • Figure 4-4: Peptides & Gastric Cancer
  • Figure 4-5: Peptides & Prostate Cancer
  • Figure 4-6: Peptides & Breast Cancer
  • Figure 5-1: Optimized Cryptic Peptides
  • Figure 5-2: Therapeutic CpG Peptide-Based Cancer Vaccine
  • Figure 5-3: Personalized Neoantigen Vaccination with Synthetic Long Peptides
  • Figure 5-4: Recombinant Peptide Vaccine
  • Figure 5-5: p53 Peptide-Pulsed Dendritic Cells Cancer Vaccine
  • Figure 6-1: Peptide Cancer Vaccine Pipeline by Phase (%), 2016
  • Figure 6-2: Peptide Cancer Vaccine Pipeline by Phase (Numbers), 2016
  • Figure 7-1: Market Drivers of Peptide Cancer Vaccines
  • Figure 7-2: Peptide Cancer Vaccine: An Active Immunotherapy
  • Figure 7-3: Peptide Cancer Vaccine: A Personalized, Targeted Therapy
  • Figure 7-4: Peptide Cancer Vaccine: Highly Efficient, High Immunogenic Response Generating
  • Figure 7-5: Peptide Cancer Vaccine: Multiple Tumors Targeting Ability
  • Figure 7-6: Peptide Cancer Vaccine: A Viable Solution to Immunotolerance
  • Figure 7-7: Peptide Cancer Vaccine: Improves the Quality Of Life & is Cost Effective
  • Figure 8-1: Challenges of Peptide Cancer Vaccine: The Parameters Related To the Clinical Trials
  • Figure 8-2: Single Antigen Based Peptide Vaccine: Highly Prone To Failure
  • Figure 8-3: Lack of Standardized Parameters for Assessing the Result of Clinical Trials
  • Figure 8-4: Variable Therapeutic Window for Different Patients
  • Figure 8-5: Cancer Immunoediting: The Three Es; Tumor Elimination, Equilibrium & Escape
  • Figure 11-1: Enzo Life Science Pipeline
  • Figure 11-2: Immatics Biotechnologies Pipeline
  • Figure 11-3: Immune Design Pipeline
  • Figure 11-4: Imugene Pipeline
  • Figure 11-5: ISA Pharmaceuticals Pipeline
  • Figure 11-6: Galena Biopharma Pipeline
  • Figure 11-7: Generex Biotechnology Pipeline
  • Figure 11-8: Lytix Biopharma Pipeline
  • Figure 11-9: Merck Clinical Pipeline
  • Figure 11-10: Onco Therapy Science Pipeline
  • Figure 11-11: Oncothyreon Pipeline
  • Figure 11-12: Sumitomo Dainippon Pharma Pipeline
  • Figure 11-13: Tapimmune Pipeline
  • Figure 11-14: Vaxon Biotech Pipeline
Back to Top